Join Growin Stock Community!

Ac immune s.a.ACIU.US Overview

US StockHealthcare
(No presentation for ACIU)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ACIU AI Insights

ACIU Overall Performance

ACIU AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ACIU Recent Performance

-2.22%

Ac immune s.a.

0.05%

Avg of Sector

-0.31%

S&P500

ACIU PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ACIU Key Information

ACIU Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ACIU Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Price of ACIU

ACIU FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ACIU Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
67.42
PB Ratio
3.66
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1643.94%
Revenue Growth (YoY)
-89.33%
Profit Growth (YoY)
-89.33%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
67.42
PB Ratio
3.66
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1643.94%
Revenue Growth (YoY)
-89.33%
Profit Growth (YoY)
-89.33%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is ACIU's latest earnings report released?

    The most recent financial report for Ac immune s.a. (ACIU) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ACIU's short-term business performance and financial health. For the latest updates on ACIU's earnings releases, visit this page regularly.

  • What is the operating profit of ACIU?

    According to the latest financial report, Ac immune s.a. (ACIU) reported an Operating Profit of -16.17M with an Operating Margin of -1,721.62% this period, representing a decline of 322.4% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ACIU's revenue growth?

    In the latest financial report, Ac immune s.a. (ACIU) announced revenue of 939K, with a Year-Over-Year growth rate of -96.32%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ACIU have?

    As of the end of the reporting period, Ac immune s.a. (ACIU) had total debt of 4.66M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ACIU have?

    At the end of the period, Ac immune s.a. (ACIU) held Total Cash and Cash Equivalents of 27.74M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ACIU go with three margins increasing?

    In the latest report, Ac immune s.a. (ACIU) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,721.62%%, and net margin of -1,688.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ACIU's profit trajectory and future growth potential.

  • Is ACIU's EPS continuing to grow?

    According to the past four quarterly reports, Ac immune s.a. (ACIU)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.16. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ACIU?

    Ac immune s.a. (ACIU)'s Free Cash Flow (FCF) for the period is -18.74M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 27.98% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.